Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 clinical trial for vispa-cel in r/r B-NHL, showing an 82% overall response rate and 67% complete response rate in a pivotal optimized subgroup. The company also reported dose escalation data from its CaMMouflage phase 1 trial for CB-011 in r/r MM, which demonstrated a 92% overall response rate and 83% complete response rate in a BCMA-naïve cohort. Caribou Biosciences is a biotechnology company developing allogeneic CAR-T cell therapies for cancer treatment.